Development of a competitive enzyme-linked immunosorbent assay for therapeutic drug monitoring of afatinib.

Afatinib Enzyme-linked immunosorbent assay Therapeutic drug monitoring Tyrosine-kinase inhibitor

Journal

Journal of pharmaceutical analysis
ISSN: 2214-0883
Titre abrégé: J Pharm Anal
Pays: China
ID NLM: 101579451

Informations de publication

Date de publication:
Feb 2019
Historique:
received: 30 03 2018
revised: 31 07 2018
accepted: 17 09 2018
entrez: 12 2 2019
pubmed: 12 2 2019
medline: 12 2 2019
Statut: ppublish

Résumé

Afatinib is an oral tyrosine kinase inhibitor (TKI) approved for treating advanced non-small cell lung cancer. It is necessary to develop a simple quantification method for TKIs in order to facilitate therapeutic drug monitoring (TDM) in clinical settings. This study sought to develop a simple and sensitive competitive enzyme-linked immunosorbent assay (ELISA) to quantify afatinib in plasma for routine pharmacokinetic applications. An anti-afatinib antibody was obtained using (S)-

Identifiants

pubmed: 30740257
doi: 10.1016/j.jpha.2018.09.002
pii: S2095-1779(18)30308-3
pmc: PMC6355467
doi:

Types de publication

Journal Article

Langues

eng

Pagination

49-54

Références

Pharm Res. 1992 Nov;9(11):1375-9
pubmed: 1475221
Cancer Chemother Pharmacol. 2012 Apr;69(4):1051-61
pubmed: 22200729
Mol Immunol. 1990 Oct;27(10):995-1000
pubmed: 2233759
Lancet Oncol. 2012 May;13(5):539-48
pubmed: 22452895
J Clin Oncol. 2013 Sep 20;31(27):3327-34
pubmed: 23816960
Drugs. 2013 Sep;73(13):1503-15
pubmed: 23982599
Biol Pharm Bull. 2013;36(12):1964-8
pubmed: 24292055
Ther Drug Monit. 2014 Feb;36(1):24-9
pubmed: 24413624
Clin Pharmacokinet. 2014 Apr;53(4):305-25
pubmed: 24566736
Lung Cancer. 2015 Apr;88(1):74-9
pubmed: 25704957
J Sep Sci. 2015 Aug;38(16):2781-8
pubmed: 26017356
Lancet Oncol. 2015 Aug;16(8):897-907
pubmed: 26156651
Biol Pharm Bull. 2015;38(10):1652-7
pubmed: 26424026
Biol Pharm Bull. 2015;38(11):1788-93
pubmed: 26521829
Biomed Chromatogr. 2016 Aug;30(8):1248-55
pubmed: 26683307
Oncol Lett. 2016 Aug;12(2):1223-1232
pubmed: 27446421
Clin Pharmacokinet. 2017 Mar;56(3):235-250
pubmed: 27470518
Ann Oncol. 2016 Nov;27(11):2103-2110
pubmed: 27601237
J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Oct 15;1033-1034:390-398
pubmed: 27639128
Anal Chim Acta. 2017 May 29;969:72-78
pubmed: 28411632
J Pharm Anal. 2018 Apr;8(2):119-123
pubmed: 29736298
Anal Biochem. 1966 Mar;14(3):328-36
pubmed: 4161471
Chem Pharm Bull (Tokyo). 1981 Jan;29(1):170-5
pubmed: 7020966

Auteurs

Rintaro Sogawa (R)

Department of Pharmacy, Saga University Hospital, 5-1-1 Nabeshima, Saga 849-8501, Japan.

Tetsuya Saita (T)

Applied Life Science Department, Faculty of Biotechnology and Life Science, Sojo University, 4-22-1 Ikeda, Kumamoto 860-0082, Japan.

Yuta Yamamoto (Y)

Applied Life Science Department, Faculty of Biotechnology and Life Science, Sojo University, 4-22-1 Ikeda, Kumamoto 860-0082, Japan.

Sakiko Kimura (S)

Department of Pharmacy, Saga University Hospital, 5-1-1 Nabeshima, Saga 849-8501, Japan.

Yutaka Narisawa (Y)

Department of Pharmacy, Saga University Hospital, 5-1-1 Nabeshima, Saga 849-8501, Japan.

Shinya Kimura (S)

Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga 849‑8501, Japan.

Masashi Shin (M)

Applied Life Science Department, Faculty of Biotechnology and Life Science, Sojo University, 4-22-1 Ikeda, Kumamoto 860-0082, Japan.

Classifications MeSH